RTP Mobile Logo
RTP TV: Part III — Renal Cell Carcinoma
Released September 2012

The third seminar of our online, integrated educational course explores topics relevant to the treatment of renal cell carcinoma. Originally held on September 13, 2012, Part III features Drs Thomas E Hutson and Robert J Motzer.

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of renal cell carcinoma (RCC).

    OVERVIEW OF ACTIVITY

    Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year and account for almost 30% of all newly diagnosed human cancers. Estimates predict that 64,770 newly diagnosed cases and 13,570 deaths from kidney cancer (renal cell and renal pelvis) will be recorded in the United States in 2012. Historically, treatment options for advanced clear cell RCC, which is resistant to conventional chemotherapeutics, were incredibly limited. Beginning in 2005, this paradigm shifted rapidly and dramatically, culminating in the FDA approval of 7 new therapeutic agents or regimens for advanced-stage disease. As such, oncologists are now faced with both the luxury and the challenge of integrating multiple effective targeted therapeutics into the practical management of RCC. Individualized recommendation for one approach versus another may only be achieved through a comprehensive understanding of the benefits and risks of each, as well as their application (or lack thereof) across various stages of the disease. This program uses a review of recent publications and presentations, faculty cases and Q&A to assist medical oncologists, radiation oncologists, nurses and other healthcare providers with the formulation of up-to-date clinical management strategies for RCC.

    LEARNING OBJECTIVES

    • Describe emerging data and ongoing research evaluating the clinical utility of angiogenesis inhibitors, novel multitargeted tyrosine kinase inhibitors and mTOR inhibitors for patients with RCC.
    • Individualize the selection of front-line systemic therapy for patients with advanced RCC through a comprehensive assessment of unique risks and benefits.
    • Recognize toxicities attributable to diverse molecular-targeted treatments for RCC, and offer preventive or emergent interventions to minimize or ameliorate these side effects.
    • Recall the scientific rationale for and efficacy of novel investigational compounds demonstrating activity in RCC.
    • Communicate the availability of ongoing clinical trial participation to appropriately selected patients with early and advanced RCC.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Thomas E Hutson, DO, PharmD
    Director, GU Oncology Program
    Co-Director, GU Center of Excellence
    Texas Oncology, PA
    Charles A Sammons Cancer Center
    Baylor University Medical Center
    Professor of Medicine, Texas A&M Health Science Center College of Medicine
    Co-Chair of GU Research, US Oncology
    Dallas, Texas

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Pfizer Inc; Consulting Agreements and Speakers Bureau: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Pfizer Inc.

    Robert J Motzer, MD
    Medical Oncologist
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Consulting Agreement: Pfizer Inc; Paid Research: Bristol-Myers Squibb Company, Eisai Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, Aveo Pharmaceuticals and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: September 2012
    Expiration date: September 2013

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):